Developmental changes in human liver CYP2D6 expression

被引:109
|
作者
Stevens, Jeffrey C. [5 ]
Marsh, Sandra A. [5 ]
Zaya, Matthew J. [5 ]
Regina, Karen J. [5 ]
Divakaran, Karthika [2 ,3 ,4 ]
Le, Min [2 ,3 ,4 ]
Hines, Ronald N. [1 ,2 ,3 ,4 ]
机构
[1] Med Coll Wisconsin, TBRC, CRI, CPPT, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Pharmacol Toxicol, Milwaukee, WI 53226 USA
[4] Childrens Hosp & Hlth Syst, Milwaukee, WI USA
[5] Pfizer Corp, Global Res & Dev, Chesterfield, MO USA
关键词
D O I
10.1124/dmd.108.021873
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Within the human cytochrome P450 family, specific forms show developmental expression patterns that can affect drug clearance, efficacy, and safety. The objective of this study was to use dextromethorphan O-demethylase activity and quantitative Western blotting to identify CYP2D6 developmental expression patterns in a large (n = 222) and developmentally diverse set of pediatric liver samples. Immunodetectable levels of CYP2D6 protein determined for selected samples across all age categories showed a significant correlation with the corresponding dextromethorphan O-demethylase activity. Of gender, ethnicity, postmortem interval, and genotype, only increasing gestational age was associated with CYP2D6 activity and protein content in prenatal samples. In contrast, both age and genotype were associated with CYP2D6 expression in postnatal samples. CYP2D6 expression in liver samples from neonates less than 7 days of age was higher than that observed in first and second trimester samples, but not significantly higher than third trimester fetal samples. In contrast, expression in postnatal samples greater than 7 days of age was substantially higher than that for any earlier age category. Higher CYP2D6 expression also was observed in liver samples from Caucasians versus African Americans. Finally, using phenotype categories inferred from genotype, CYP2D6 activity was higher in postnatal samples predicted to be extensive or intermediate metabolizers versus poor metabolizers. These results suggest that age and genetic determinants of CYP2D6 expression constitute significant determinants of interindividual variability in CYP2D6-dependent metabolism during ontogeny.
引用
收藏
页码:1587 / 1593
页数:7
相关论文
共 50 条
  • [21] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Tolledo, Cole
    Stocco, Marlaina R.
    Miksys, Sharon
    Gonzalez, Frank J.
    Tyndale, Rachel F.
    MOLECULAR NEUROBIOLOGY, 2020, 57 (06) : 2509 - 2520
  • [22] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Cole Tolledo
    Marlaina R. Stocco
    Sharon Miksys
    Frank J. Gonzalez
    Rachel F. Tyndale
    Molecular Neurobiology, 2020, 57 : 2509 - 2520
  • [23] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [24] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [25] HIGH-YIELD EXPRESSION OF FUNCTIONALLY ACTIVE HUMAN LIVER CYP2D6 IN YEAST-CELLS
    KRYNETSKI, EY
    DRUTSA, VL
    KOVALEVA, IE
    LUZIKOV, VN
    PHARMACOGENETICS, 1995, 5 (02): : 103 - 109
  • [26] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [27] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [28] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [29] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [30] Enantioselective metabolism of primaquine by human CYP2D6
    Fasinu, Pius S.
    Tekwani, Babu L.
    Nanayakkara, N. P. Dhammika
    Avula, Bharathi
    Herath, H. M. T. Bandara
    Wang, Yan-Hong
    Adelli, Vijender R.
    Elsohly, Mahmoud A.
    Khan, Shabana I.
    Khan, Ikhlas A.
    Pybus, Brandon S.
    Marcsisin, Sean R.
    Reichard, Gregory A.
    McChesney, James D.
    Walker, Larry A.
    MALARIA JOURNAL, 2014, 13